ACT Capital Partners, L.P.’s Kyverna Therapeutics KYTX Stock Holding History

ACT Capital Partners, L.P.’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$272K	Buy	+40,000	New	+$316K	0.18%	46

Other funds holding KYTX

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

ACT Capital Partners, L.P.'s KYTX Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Kyverna Therapeutics (KYTX) in Q3 2026: 40,000 shares worth $272K. The stake represents 0.18% of the portfolio and ranks #46 among its holdings.

41 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

ACT Capital Partners, L.P. held 40,000 shares of Kyverna Therapeutics worth $272K as of Q3 2026.
Kyverna Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Kyverna Therapeutics made up 0.18% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #46 holding.
41 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.